Royal London Asset Management Ltd. Purchases 6,060 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Royal London Asset Management Ltd. lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,533 shares of the company's stock after acquiring an additional 6,060 shares during the period. Royal London Asset Management Ltd. owned about 0.05% of Neurocrine Biosciences worth $5,938,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences during the second quarter valued at approximately $28,000. Innealta Capital LLC purchased a new position in Neurocrine Biosciences during the second quarter valued at approximately $30,000. EdgeRock Capital LLC purchased a new position in Neurocrine Biosciences during the second quarter valued at approximately $35,000. Blue Trust Inc. grew its position in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock valued at $40,000 after purchasing an additional 220 shares in the last quarter. Finally, Plato Investment Management Ltd lifted its stake in Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company's stock valued at $59,000 after acquiring an additional 130 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NBIX. BMO Capital Markets dropped their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research note on Thursday, October 17th. Piper Sandler upgraded shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research note on Friday, October 4th. HC Wainwright restated a "buy" rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Finally, Needham & Company LLC restated a "hold" rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Neurocrine Biosciences has an average rating of "Moderate Buy" and a consensus target price of $163.91.

Insiders Place Their Bets

In other news, insider Jude Onyia sold 2,331 shares of the firm's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares of the company's stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences Stock Up 0.3 %

NASDAQ NBIX traded up $0.42 during midday trading on Monday, hitting $128.56. The company had a trading volume of 350,761 shares, compared to its average volume of 867,787. The stock has a market cap of $13.02 billion, a price-to-earnings ratio of 34.35 and a beta of 0.34. The firm has a fifty day simple moving average of $120.33 and a two-hundred day simple moving average of $130.98. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.